Insights That Move the GPCR Field Forward

Clean data can still mislead if the underlying assumptions aren’t tested. Schild analysis is one of the few tools that tells you whether your “competitive antagonist” is actually behaving competitively. This week, we help you tighten your interpretations and strengthen your decisions at the bench and in discovery. Breakthroughs this week: McGPCR multimodal model; Endocrine Metabolic GPCRs 2026; Pfizer–Metsera acquisition.

Drug discovery often assumes receptor inhibition follows simple rules—agonist binds, antagonist blocks, and data fit neatly into predictable curves. Yet, any pharmacologist who’s pushed beyond textbook theory knows: biology rarely plays fair. Schild analysis remains one of the few conceptual anchors that can tell us when “simple” truly is simple—and when deeper receptor dynamics are at play.